TransMedics Group, Inc. (TMDX)

Market Cap	1.86B
Revenue (ttm)	151.08M
Net Income (ttm)	-17.78M
Shares Out	32.63M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	454,097
Open	55.21
Previous Close	54.87
Day's Range	55.18 - 57.16
52-Week Range	38.86 - 99.63
Beta	1.46
Analysts	Buy
Price Target	89.60 (+57.44%)
Earnings Date	Nov 2, 2023

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for dou...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 2, 2019
• Employees: 212
• Stock Exchange: NASDAQ
• Ticker Symbol: TMDX

Financial Performance

In 2022, TMDX's revenue was $93.46 million, an increase of 208.83% compared to the previous year's $30.26 million. Losses were -$36.23 million, -18.06% less than in 2021.

Analyst Forecast

According to 5 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is $89.6, which is an increase of 57.44% from the latest price.

Price Target

$89.6

(57.44% upside)

Analyst Consensus: Buy